You can also browse the topics below to find what you are looking for.
You can also sort the topics above the navigation bar.
The EPA sets out the following criteria for efficacy against Covid-19:
1. The product must be a hospital or broad-spectrum disinfectant product registered with EPA.
2. For an emerging enveloped virus, the product must have acceptable efficacy data previously submitted to and reviewed by the Agency against one non-enveloped virus (Poliovirus).
The Rejuvenate™ line of disinfectants (concentrate, ready-to-use and premoistened wipes) have demonstrated effectiveness against viruses similar to Covid-19 on hard, nonporous surfaces. Therefore, Rejuvenate can be used against 2019-nCoV when used in accordance with the directions for use against Poliovirus type 1 on hard, non-porous surfaces. Referent to January 27,
is a registered trademark of Virox Technologies Inc., the developer of the AHP® technology.
Virox ProBeauty™ is a division of Virox® Technologies Inc.
© 2003 - VIROX TECHNOLOGIES INC.